MHRA Invites Views on Proposed UK Pre-Market Medical Device Regulation Changes

MHRA Invites Views on Proposed Changes to UK Medical Device Regulation

Date: 11 May 2026

On 8 May 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published new draft pre-market regulatory requirements for medical devices and in vitro diagnostic medical devices (IVDs) placed on the UK market through the World Trade Organization (WTO) notification portal. The draft is titled the Medical Devices (Amendment) Regulations 2026.

The notification gives WTO members an opportunity to comment on the proposed pre-market requirements. The medical device industry, notified bodies, healthcare providers and patients are also invited to share their views on the impact of the proposed changes through an MHRA survey. Responses will inform the impact assessment and future implementation of the regulations.

The draft regulations set out patient-centred and proportionate regulatory requirements intended to prioritise patient safety and access to innovative medical technologies. The requirements aim to:

• Accelerate market access for safe and innovative medical devices and support economic growth and innovation in the UK medical device sector.
• Introduce a framework to enable faster market entry for devices already approved by regulators in Australia, Canada and the United States.
• Require healthcare institutions that implant medical devices to provide patients with implant cards containing information about the implanted device, improving adverse event management and patient transparency.
• Mandate the use of Unique Device Identification (UDI) to enable precise identification and traceability throughout the device lifecycle.
• Align the classification of IVDs with International Medical Device Regulators Forum (IMDRF) standards.
• Align the essential requirements for UK medical devices with international best practice.
• Strengthen requirements for retention of technical documentation and ensure this information is kept for an appropriate period.
• Introduce new requirements for custom-made devices to improve traceability and enable electronic prescribing.
• Require manufacturers to ensure that claims about their medical devices are consistent with the statement of intended purpose.

These proposals support the government's objective in the Life Sciences Sector Plan for the UK to become one of the three fastest countries in Europe for medical device approvals by 2030, while safeguarding patient access to medical devices.

MHRA welcomes views relevant to you or your organisation. The survey closes on Friday 19 June 2026 at 11:59 pm UK time.

Source and applicability note

Source: Medicines and Healthcare products Regulatory Agency (MHRA). Original article date: 11 May 2026. Source URL: https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation

This article is compiled from public information published by MHRA. Specific requirements remain subject to the regulator's latest official publications.

AIMEILI Regulatory Interpretation

The MHRA draft Medical Devices (Amendment) Regulations 2026 is a significant step in the independent reform of the UK medical device regulatory system following the UK's departure from the EU. It proposes concrete regulatory changes and seeks international comment through the WTO notification and public survey. For manufacturers targeting the UK market, including Chinese exporters and companies planning entry into Great Britain, the reform will have direct implications for registration pathways, technical documentation, classification, labelling and post-market surveillance. Companies should monitor subsequent developments and prepare compliance measures in advance.

Registration pathways and the proposed fast-track

The draft introduces a fast-track framework allowing devices already approved in Australia, Canada or the United States to enter the UK market more quickly. If a product has already obtained TGA, Health Canada or FDA approval, companies may potentially use this route to shorten UK market entry time. However, detailed eligibility criteria and document review standards have not yet been clarified and should be tracked in implementing rules. The draft also emphasises alignment with international best practice, so future UK technical documentation requirements may be closer to EU MDR or IMDRF guidance. Existing CE or FDA technical files may have gaps and should be assessed for additional clinical evaluation, performance verification or risk management documentation.

IVD classification alignment with IMDRF

The draft explicitly aligns IVD classification with IMDRF standards. This is a major change because the UK previously followed EU classification rules. For IVD manufacturers, redefinition of product classification may affect the conformity assessment route, for example moving from self-declaration to notified body review. Companies should compare current and proposed classifications and prepare in advance for any additional testing or documentation.

UDI, implant cards and labelling

The mandatory UDI requirement will impose hard requirements for lifecycle traceability. Devices exported to the UK must bear UDI and ensure data is uploaded to the relevant database. Companies need to establish or update UDI management systems, adjust labels and packaging, and coordinate with supply chain parties. In addition, the draft requires healthcare institutions implanting devices to provide implant cards to patients. This means patient-readable information must be provided in labelling or accompanying documents, increasing compliance costs.

Technical documentation retention and custom-made devices

The draft strengthens technical documentation retention requirements by requiring documentation to be kept for an appropriate period, potentially covering at least the product lifecycle plus a defined number of years, similar to the 10-year or 15-year requirements under EU MDR. Companies should review current retention policies and ensure document management systems can meet the requirements. New requirements for custom-made devices emphasise traceability and electronic prescribing. Companies supplying custom-made devices, such as 3D-printed prostheses, to the UK may need to establish electronic prescription processes and traceability systems.

Claims and intended purpose consistency

The draft requires manufacturers to ensure that claims about their medical devices are consistent with the intended purpose statement. All performance claims in promotional materials, labels and instructions for use must be substantiated and must not exceed the intended purpose. Companies should strictly review marketing materials for exaggerated wording.

Business Impact

The reform will affect the full compliance chain for UK market access. Companies should conduct a gap analysis covering UKCA marking applications, technical file completeness, UDI implementation, classification transition, labelling and instructions for use, implant card requirements where applicable, technical documentation retention, custom-made device processes and post-market surveillance arrangements. Companies may also consider responding to the MHRA survey to participate in the rule-making process and seek appropriate transitional arrangements. AIMEILI regulatory affairs team will continue to monitor the draft regulations and provide compliance advisory support.

FAQ

Can the 11 May 2026 MHRA consultation be used directly as a basis for regulatory submission?

No. The article is intended for preliminary understanding and project assessment. Formal submissions must be based on the latest requirements of the target regulatory authority, product classification conclusions and the company's actual documentation.

What should companies do first after seeing this update?

Companies should first conduct a documentation gap assessment to confirm whether the update affects the registration pathway, technical documentation, labelling, quality management system or post-market maintenance.

Content review and scope

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI International Medical Device Registration Project Team. Source principle: Official regulatory authorities, international organisations, standards bodies and public regulatory materials are prioritised; industry media and project experience are used only as supporting judgement. Scope: This article is for preliminary understanding, document preparation and project planning and does not replace the formal requirements of the target regulatory authority, testing conclusions or legal advice.